NASDAQ:BLCM - Bellicum Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.46
▼ -0.01 (-0.68%)

This chart shows the closing price for BLCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bellicum Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLCM

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Bellicum Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.46.

This chart shows the closing price for BLCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Bellicum Pharmaceuticals. This rating has held steady since October 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/30/2020LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
10/30/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$4.50High
3/13/2020Raymond JamesLower Price TargetOutperform$40.00 ➝ $17.00High
2/14/2020Wells Fargo & CompanyBoost Price Target$4.00 ➝ $18.00Low
8/9/2018CitigroupLower Price TargetBuy ➝ Buy$220.00 ➝ $190.00High
8/7/2018Cantor FitzgeraldSet Price TargetBuy$180.00High
5/9/2018Cantor FitzgeraldSet Price TargetBuy$180.00Medium
4/11/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$83.00 ➝ $68.50High
4/11/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00 ➝ $180.00High
3/13/2018Cantor FitzgeraldSet Price TargetBuy$100.00Low
2/23/2018Cantor FitzgeraldSet Price TargetBuy$100.00High
2/16/2018CitigroupBoost Price TargetBuy ➝ Hold$240.00 ➝ $270.00High
1/31/2018SunTrust BanksLower Price TargetHold ➝ Buy$180.00High
1/31/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$120.00 ➝ $100.00High
1/31/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$60.00High
12/12/2017Raymond JamesReiterated RatingBuyHigh
9/14/2017Jefferies Financial GroupReiterated RatingBuy$160.00Low
8/10/2017Jefferies Financial GroupReiterated RatingBuy$180.00 ➝ $160.00High
8/9/2017Raymond JamesSet Price TargetBuy$290.00 ➝ $180.00High
6/27/2017Raymond JamesReiterated RatingBuyLow
6/27/2017Wells Fargo & CompanyReiterated RatingOutperform$310.00Low
6/26/2017Cantor FitzgeraldReiterated RatingOverweight$350.00Low
6/24/2017Cantor FitzgeraldSet Price TargetBuy$320.00Low
6/24/2017LADENBURG THALM/SH SHSet Price TargetBuy$310.00Low
5/10/2017Cantor FitzgeraldReiterated RatingOverweight$320.00Low
5/9/2017Jefferies Financial GroupLower Price TargetBuy$190.00 ➝ $180.00High
3/14/2017Cantor FitzgeraldReiterated RatingBuy$320.00Medium
3/14/2017Jefferies Financial GroupReiterated RatingBuy$220.00 ➝ $190.00Medium
3/8/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$295.00High
2/27/2017Jefferies Financial GroupReiterated RatingBuy$220.00N/A
2/23/2017Cantor FitzgeraldSet Price TargetBuy$320.00N/A
(Data available from 1/18/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/19/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Bellicum Pharmaceuticals logo
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.
Read More

Today's Range

Now: $1.46
Low: $1.45
High: $1.50

50 Day Range

MA: $1.69
Low: $1.43
High: $2.09

52 Week Range

Now: $1.46
Low: $1.43
High: $8.15

Volume

8,864 shs

Average Volume

44,910 shs

Market Capitalization

$12.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Bellicum Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Bellicum Pharmaceuticals in the last twelve months: Zacks Investment Research.
View the latest analyst ratings for BLCM.

What is the current price target for Bellicum Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Bellicum Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Bellicum Pharmaceuticals in the next year.
View the latest price targets for BLCM.

What is the current consensus analyst rating for Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BLCM.

How do I contact Bellicum Pharmaceuticals' investor relations team?

Bellicum Pharmaceuticals' physical mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company's listed phone number is (832) 384-1100 and its investor relations email address is [email protected] The official website for Bellicum Pharmaceuticals is www.bellicum.com.